Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 10/20 | 0.40 |
| ▸ | FPR1 | P21462 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28376667 | 0.93 | FPR2 (0.41) | FPR2FPR1GAAUSP30NFKB1 | |
| SCHEMBL21900482 | 0.93 | FPR2 (0.41) | FPR2FPR1GAAUSP30NFKB1 | |
| SCHEMBL8299289 | 0.88 | FPR2 (0.40) | FPR2FPR1GAANFKB1NFKB2 | |
| SCHEMBL8300928 | 0.86 | FPR1 (0.39) | FPR2FPR1GAANFKB1NFKB2 | |
| SCHEMBL8298740 | 0.83 | F10 (0.40) | FPR2FPR1SCN9A | |
| SCHEMBL14488738 | 0.83 | F10 (0.40) | FPR2FPR1SCN9A | |
| SCHEMBL31347254 | 0.81 | MCHR1 (0.46) | FPR2FPR1 | |
| SCHEMBL16493351 | 0.80 | FPR2 (0.56) | FPR2FPR1GAA | |
| SCHEMBL23168331 | 0.80 | F10 (0.46) | FPR2FPR1USP30AAK1 | |
| SCHEMBL23168328 | 0.80 | F10 (0.46) | FPR2FPR1USP30AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698275-A1 | PYRROLIDINONE UREA FPR2 AGONISTS | Bristol-Myers Squibb Company (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4698516-A1 | PYRROLIDINONE UREA FPR2 AGONISTS | Bristol-Myers Squibb Company (US) | 2026-02-25 | — | — | EP | disclosed |
| WO-2024220482-A1 | PYRROLIDINONE UREA FPR2 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024220453-A1 | PYRROLIDINONE UREA FPR2 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-24 | — | — | WO | disclosed |
| US-7235544-B2 | for use in conjunction with thrombolytic agents, thus permitting the use of a lower dose of thrombolytic agent; treatment of acute vascular diseases; may have potential in neurogenerative diseases such as Parkinson's and Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235544-B2 | for use in conjunction with thrombolytic agents, thus permitting the use of a lower dose of thrombolytic agent; treatment of acute vascular diseases; may have potential in neurogenerative diseases such as Parkinson's and Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| WO-2004110997-A1 | 3- SULFONYLAMINO- PYRROLIDINE- 2- ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |